No Data
Wuxi Bio (02269): Miao Jingwen has been appointed as a non-executive director.
Wuxi Bio (02269) announced that effective from November 20, 2024: Dr. Wu Yibing has resigned from his non...
The opening ceremony of the Guangdong-Hong Kong-Macao Greater Bay Area International Clinical Trial Institute.
The "Guangdong-Hong Kong-Macao Greater Bay Area International Clinical Trial Institute", established by the special zone government and fully owned, officially opened today (21st) at the Hong Kong Park in the Hetao Shenzhen-Hong Kong Science and Technology Innovation Cooperation Zone. The "Guangdong-Hong Kong-Macao Greater Bay Area International Clinical Trial Center" in Shenzhen Park also opened on the same day. The "one institute and one center" has become the first benchmark for the coordinated development of the "one zone and two parks" in the Hetao Shenzhen-Hong Kong Science and Technology Innovation Cooperation Zone. Secretary for Administration and Home Affairs, Cheuk Wing-hing, stated that the National "14th Five-Year Plan" clearly supports Hong Kong in building an international innovation and technology center. The "Development Plan for Shenzhen Park in the Hetao Shenzhen-Hong Kong Science and Technology Innovation Cooperation Zone" also strongly supports the coordinated development of science and te
Behind the Hong Kong stock CXO's sideways oscillation, foreign investors continue to sell while domestic investors accelerate their entrance.
Recently, the public fund medical hold positions data for Q3 2024 has been gradually disclosed, with a noticeable increase in CXO positions. Additionally, the Hong Kong Stock Connect funds have significantly bought CXO symbol stocks in the past 60 days, reflecting the current optimistic attitude of domestic funds towards the subsequent rebound of the CXO sector.
The bullish market stimulated the Hong Kong stock pharmaceutical sector, with Laikai Pharmaceutical soaring nearly 20%.
Statistics from the Capital Research Department of Silver (Hong Kong) show that the number of innovative drugs IND and NDA has returned to growth after hitting a low in 2022. In the third quarter of this year, 1033 drug clinical approvals were granted, a 25% year-on-year increase, with a total of 8 first-class innovative drugs approved for marketing, doubling year-on-year.
Wuxi Bio (2269.HK): In the first half of 2024, the company's adjusted shareholder profit attributable to shareholders decreased by 20.7% year-on-year.
In the first half of 24, the company's adjusted shareholder attributable profit decreased by 20.7% year-on-year: In the first half of 24, the company's revenue increased by 1.0% year-on-year to 8.57 billion yuan, excluding the impact of COVID-19, non-COVID revenue increased by 7.7%. Due to the decrease in high gross margin revenue from the R-end and the impact of overseas factory production ramp-up, the company's gross margin decreased by 2.8 percentage points year-on-year to 39.1%. The company's sales, management, research and development, and financial expense ratios increased by 1.5, 1.0, 0, and -0.1 percentage points year-on-year to 2.6%, 9.0%, 4.0%, and 0.8%, respectively. In summary, the company's net profit attributable to shareholders decreased by 33.9% year-on-year to 1.5 billion yuan, with the net profit margin decreasing by 9.2 percentage points year-on-year to 17.5%. If adjusted for share-based compensation expenses, foreign exchange gains, and fair value changes in equity investments, the company
Wuxi Bio plans to expand the production capacity of its German plant by adding filling production lines.
Wuxi Bio (02269.HK) announced that the company will expand the production capacity of the Levo Kösen base in Germany and build a new isolator filling prefilled syringe production line. The company stated that this expansion will optimize the production layout of the base, providing more efficient solutions for the CRDMO services of multiple products.
No Data
No Data